Transcription of Summary Document for Interim Clinical Considerations
{{id}} {{{paragraph}}}
Example: bachelor of science
Summary Document for Interim Clinical Considerations
1CS321571-WSummary Document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized or Approved in the United StatesCategoryPfizer-BioNTechModerna Janssen Preferential recommendationmRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) are preferred over Janssen COVID- 19 vaccine for the primary series and booster doses. Age groups5 through 11 years of age12 years of age and older18 years of age and older 18 years of age and older vaccine typemRNAmRNAmRNAR eplication-incompetent adenovirus type 26 vectorDose10 g (orange cap) 30 g (purple cap) 30 g (gray cap) 100 g (primary series and additional primary dose) 50 g (booster dose)5 1010 viral particlesDosage (volume) mL mL (primary series and additional dose formoderately or severely immunocompromised persons) mL (booster dose) mLPrimary series doses 2 22 1 Additional doses for moderately or severely immunocompromised pers
Mar 07, 2022 · The small risk of myocarditis associated with mRNA COVID-19 vaccines, particularly in males ages 12-39 years, might be reduced and peak antibody responses and vaccine . effectiveness may be increased with a longer interval; up to …
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: